Search Results - "Ortuzar, Waldo Feliu"

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study by O'Malley, David M, Neffa, Maryna, Monk, Bradley J, Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M, Bagameri, Andrea, Wang, Edward W, Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona

“…Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising…”
Get full text

256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699) by Perez, Cesar, Wesolowski, Robert, Wilky, Breelyn, Feliu, Waldo Ortuzar, Zhang, Hong, Shapiro, Irina, Wijatyk, Anna, Kaleta, Remigiusz, Trent, Jonathan

“…BackgroundZalifrelimab is a fully human monoclonal antibody against cytotoxic T-lymphocyte -associated protein 4 (CTLA-4). Preliminary data demonstrated…”
Get full text

479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results by El-Khoueiry, Anthony, Bullock, Andrea, Tsimberidou, Apostolia, Mahadevan, Daruka, Wilky, Breelyn, Twardowski, Przemyslaw, Bockorny, Bruno, Moser, Justin, Feliu, Waldo Ortuzar, Grossman, Joseph, Rosenthal, Katherine, O’Day, Steven, Gordon, Michael

“…BackgroundAGEN1181 is a novel anti-CTLA-4 antibody with enhanced FcyR-dependent functionality, engineered to bind high and low binding alleles of FcyRIIIA,…”
Get full text

267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer by O’Malley, David, Feliu, Waldo Ortuzar, Ray-Coquard, Isabelle, O’Neal, Michael, Alexandre, Jerome, Cole, Julie, Ludwig, Robert, Nallewar, Madhavi, Buell, Jennifer, Kaleta, Remigiusz, Wijatyk, Anna, Borisovskaya, Victoria

“…BackgroundThe phenomenon of pseudoprogression (PsP) may appear with cancer immunotherapy. The underlying etiology is not fully elucidated, tumor flare is the…”
Get full text

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer by O'Malley, David M., Oaknin, Ana, Monk, Bradley J., Selle, Frédéric, Rojas, Carlos, Gladieff, Laurence, Berton, Dominique, Leary, Alexandra, Moore, Kathleen N., Estevez-Diz, Maria D.P., Hardy-Bessard, Anne-Claire, Alexandre, Jérôme, Opperman, Christina P., de Azevedo, Carla Rameri A.S., Randall, Leslie M., Feliu, Waldo Ortuzar, Ancukiewicz, Marek, Ray-Coquard, Isabelle

“…This phase II clinical trial evaluated the safety and antitumor activity of balstilimab, an anti-PD-1 antibody, in patients with previously-treated,…”
Get full text

Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors by Tolcher, Anthony W., Carvajal, Richard D., El-Khoueiry, Anthony B., Ortuzar Feliu, Waldo, Zang, Hong, Ancukiewicz, Marek, Shapiro, Irina, Strauss, James Fredric

“…Abstract only 2634 Background: CD137 is a member of the tumor necrosis factor receptor superfamily that functions as a potent co-stimulator of both adaptive…”
Get full text

Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer (041) by Bockorny, Bruno, Matulonis, Ursula, O'Day, Steven, Margolin, Kim, El-Khoueiry, Anthony, Wilky, Breelyn, Sanborn, Rachel, Balmanoukian, Ani, Bullock, Andrea, Wulf, Gerburg, Kristedja, Timothy, Hanna, Diana, Grossman, Joseph, Feliu, Waldo Ortuzar, Rosenthal, Katherine, Godwin, James, Patel, Jaymin, Beagle, Brandon, Bullock, Bonnie, Rawal, Bhupendra, Cole, Hunter, Song, Xin (James), Mahadevan, Daruka, Gordon, Michael

Get full text

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) by El-Khoueiry, Anthony B., Fakih, Marwan, Gordon, Michael S., Tsimberidou, Apostolia Maria, Bullock, Andrea J., Wilky, Breelyn A., Trent, Jonathan C., Margolin, Kim Allyson, Mahadevan, Daruka, Balmanoukian, Ani Sarkis, Sanborn, Rachel E., Schwartz, Gary K., Bockorny, Bruno, Moser, Justin C, Grossman, Joseph Elan, Ortuzar Feliu, Waldo Ignacio, Rosenthal, Katherine, O'Day, Steven, Lenz, Heinz-Josef, Schlechter, Benjamin L.

“…LBA8 Background: BOT promotes optimized T cell priming, activation and memory formation by strengthening antigen presenting cell/T cell co-engagement. As an…”
Get full text

AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies by O'Day, Steven, Ramamurthy, Chethan, Bullock, Andrea J., El-Khoueiry, Anthony B., Ohanjanian, Lernik, Wijatyk, Anna, Ortuzar Feliu, Waldo Ignacio, Shapiro, Irina, Ancukiewicz, Marek, Chand, Dhan, Buell, Jennifer, Gordon, Michael S.

“…Abstract only TPS3157 Background: AGEN1181 is a novel Fc-optimized anti-CTLA4 antibody, currently being evaluated in an ongoing multi-center, open-label, phase…”
Get full text

RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer by O'Malley, David M, Randall, Leslie M, Jackson, Camille Gunderson, Coleman, Robert L, Hays, John L, Moore, Kathleen N, Naumann, R Wendel, Rocconi, Rodney P, Slomovitz, Brian M, Tewari, Krishnansu S, Ancukiewicz, Marek, Feliu, Waldo Ortuzar, Monk, Bradley J

“…Balstilimab (anti-programmed death 1) and zalifrelimab (anti-CTLA-4) are two new checkpoint inhibitors that have emerged as promising investigational agents…”
Get full text

BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM) by Mason, Warren P., de Robles, Paula, Borodyansky, Laura, Hitron, Matthew, Ortuzar, Waldo Feliu, Khan, Waheed, Xu, Bo, Li, Wei, Li, Youzhi, Li, C J

“…Abstract only e13525 Background: Napabucasin, a first-in-class cancer stemness inhibitor in clinical development, suppresses cancer stemness by targeting…”
Get full text

BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer by Larson, Tim, Ortuzar, Waldo Feliu, Bekaii-Saab, Tanios S., Becerra, Carlos, Ciombor, Kristen Keon, Hubbard, Joleen Marie, Edenfield, William Jeffery, Shao, Spencer H., Grothey, Axel, Borodyansky, Laura, Xu, Bo, Li, Wei, Li, Youzhi, Li, Chiang, Khan, Waheed

“…Abstract only 677 Background: Napabucasin a first-in-class cancer stemness inhibitor in clinical development, suppresses cancer stemness by targeting…”
Get full text

BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC) by El-Rayes, Bassel F., Richards, Donald A., Cohn, Allen Lee, Richey, Stephen Lane, Feinstein, Trevor, Kundranda, Madappa N., El-Khoueiry, Anthony B., Melear, Jason M., Braiteh, Fadi S., Hitron, Matthew, Ortuzar, Waldo Feliu, Khan, Waheed, Xu, Bo, Li, Wei, Li, Youzhi, Li, C J

“…Abstract only 4077 Background: Napabucasin, a first-in-class cancer stemness inhibitor in clinical development, suppresses cancer stemness by targeting…”
Get full text

Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC) by Graham, Christopher N., Knox, Hediyyih N., Winfree, Katherine B., Hess, Lisa M., Liu, Jingyi, Ortuzar, Waldo Feliu, Zinner, Ralph

“…Abstract only 263 Background: The PRONOUNCE trial was a phase III, randomized, open-label U.S. study comparing pemetrexed (PemC) with bevacizumab (PCB) in the…”
Get full text

Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) by Zinner, Ralph, Ross, Helen J., Weaver, Robert, Govindan, Ramaswamy, Holden, Viran R., Chowhan, Naveed Mahfooz, Beck, J. Thaddeus, Waterhouse, David Michael, Modiano, Manuel, Rao, Vijay Phooshkooru, Liu, Jingyi, Koustenis, Andrew, Melemed, Symantha, Guba, Susan C., Ortuzar, Waldo Feliu, Desaiah, Durisala, Spigel, David R., Obasaju, Coleman K.

“…Abstract only LBA8003 Background: PemC and PCB are regimens used for first-line treatment of advanced NS-NSCLC. The primary objective was to compare…”
Get full text

Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) by Zinner, Ralph, Ross, Helen J., Weaver, Robert, Govindan, Ramaswamy, Holden, Viran R., Chowhan, Naveed Mahfooz, Beck, J. Thaddeus, Waterhouse, David Michael, Modiano, Manuel, Rao, Vijay Phooshkooru, Liu, Jingyi, Koustenis, Andrew, Melemed, Symantha, Guba, Susan C., Ortuzar, Waldo Feliu, Desaiah, Durisala, Spigel, David R., Obasaju, Coleman K.

“…Abstract only LBA8003 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June 3, 2013, and in the Annual…”
Get full text